MRNA
Moderna, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 94.02K | $17.71M | n/a | n/a |
| Q2 2026 | 145 | +2 | 263.41M | $18.44B | +8 | −7 |
| Q1 2026 | 147 | +3 | 253.55M | $12.87B | +6 | −4 |
| Q4 2025 | 144 | +3 | 257.18M | $7.59B | +5 | −1 |
| Q3 2025 | 18 | +1 | 165.07M | $4.26B | +2 | −2 |
| Q2 2025 | 15 | 0 | 160.48M | $4.43B | +1 | −1 |
| Q1 2025 | 12 | -2 | 69.84M | $1.98B | +1 | −3 |
| Q4 2024 | 14 | -1 | 78.84M | $3.28B | +3 | −4 |
| Q3 2024 | 14 | -2 | 62.86M | $4.20B | +2 | −4 |
| Q2 2024 | 16 | n/a | 65.32M | $7.75B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | TD Waterhouse Canada Inc. | 72.59K | +2042.6% | $13.72M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 21.42K | +23.1% | $3.99M | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 717 holders, 306.78M shares, $15.39B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 39.15K sh · $8.64M
Officer · 450 sh · $96,368
Officer · 38.77K sh · $8.28M
Officer · 40.28K sh · $5.88M
Officer · 40.29K sh · $5.81M
Officer · 19.84K sh · $2.67M
Officer · 15.00K sh · $2.02M
Officer · 3.47K sh · $485,766
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology